Immunology · Inborn Error of Immunity With Autoinflammation

The Long View: Building Your Care Team and Managing Your Future

At a Glance

People with inborn errors of immunity and autoinflammation benefit from a coordinated team led by an immunologist, with monitoring tailored to their subtype and symptoms. Keeping health records and seeking mental-health support can make long-term care safer and more manageable.

Managing an Inborn Error of Immunity (IEI) with autoinflammation is a marathon, not a sprint. Because these conditions affect multiple systems—the blood, the skin, the joints, and the immune defenses—no single doctor can manage them alone ^[1]^[2]. Long-term success depends on building a “home” for your care: a multidisciplinary team that communicates and an individualized monitoring plan that catches complications early ^[3]^[4].

Building Your Multidisciplinary Team

A well-rounded care team is essential for navigating the dual nature of your diagnosis. Your “roster” should ideally include:

Immunologist: The lead strategist for your overall immune health and antibody replacement therapy ^[2].
Rheumatologist: The expert in managing the “heat” of autoinflammation and selecting targeted biologics ^[5].
Hematologist: Crucial for monitoring blood counts and bone marrow health, especially in conditions like VEXAS ^[6].
Geneticist / Genetic Counselor: To interpret sequencing results, provide counseling for family members, and stay updated on new research ^[7].
Organ Specialists: Depending on your subtype, you may need a Dermatologist (skin), Gastroenterologist (gut), or Cardiologist (heart) ^[8]^[9].

When vetting specialists, don’t be afraid to ask how many patients with your specific subtype they have treated. Because these diseases are rare, it is often better to have a doctor who is willing to consult with international experts than one who claims to have all the answers ^[3].

The Artifacts of Your Care

You are the most important historian of your disease. To make the most of your appointments, always have these “artifacts” ready:

Full Genetic Reports: Not just a summary, but the actual lab report showing the specific mutation and its “variant” classification ^[7].
The “Flare & Infection” Log: A simple calendar or app tracking when you had fevers, rashes, or needed antibiotics. This helps doctors see the rhythm of your disease ^[2].
Lab Trends: Keep a folder of your CBCs (Complete Blood Counts) and Inflammatory Markers (CRP/Ferritin). Trends—like a slowly rising MCV or falling platelet count—are more informative than any single result ^[10].

Individualized Long-Term Monitoring

Monitoring is tailored to the specific risks of your subtype and symptoms, rather than a fixed universal schedule.

VEXAS Syndrome: The priority is watching for Myelodysplastic Syndrome (MDS) and blood clots. Your team may track your “Variant Allele Fraction” and perform bone marrow reviews, but this is driven by cytopenias or clinical concern, not a routine fixed schedule ^[11]^[12].
HOIL-1 Deficiency: Monitoring focuses on the heart and muscles. Cardiac and muscle surveillance should reflect your symptoms, genotype, and specialist plan to check for amylopectinosis (the buildup of abnormal sugars) ^[13]^[9].
All Subtypes: Doctors will monitor for “organ damage” (scars from chronic inflammation) and the side effects of long-term treatments like steroids or biologics ^[14]^[5].

Living with the “Invisible” Burden

The psychological toll of living with a rare, unpredictable disease is significant. Patients often report lower quality of life due to chronic fatigue, the anxiety of waiting for lab results (lab anxiety), and the burden of navigating an invisible illness ^[15]^[16].

Rather than defaulting to total “self-isolation,” work with your team on an individualized infection-prevention plan that allows safe social participation. It is common to feel a sense of “stigma” or “nondisclosure” in the workplace or at school because your symptoms aren’t always visible to others ^[17]. Shared decision-making with your doctors—where your personal values, school/work accommodations, and access to mental-health support are prioritized—is the best way to ensure your treatment plan supports a life that is full, not just “managed” ^[4]^[18].

Common questions in this guide

What specialists should be part of my care team?

An immunologist is often the lead clinician for immune health and antibody replacement therapy, while a rheumatologist manages inflammation. A hematologist, geneticist or genetic counselor, and specialists in areas such as dermatology, gastroenterology, or cardiology may be added based on your subtype and symptoms.

How often will I need blood tests and other monitoring?

There is no single schedule for everyone with an inborn error of immunity and autoinflammation. Testing should be tailored to your subtype, symptoms, blood counts, treatments, and any changes that raise concern, so ask which tests are routine and which are triggered by symptoms.

What health information should I keep and share with my doctors?

Keep the complete genetic laboratory report, a timeline of fevers, rashes, infections, and antibiotic use, and records showing trends in your complete blood counts, CRP, and ferritin. Sharing an organized copy with your specialists and primary care clinician can help them understand changes over time.

What does long-term monitoring involve for VEXAS syndrome?

For VEXAS, clinicians watch for myelodysplastic syndrome and blood clots. They may review the variant allele fraction and bone marrow findings when low blood counts or other clinical concerns arise; these checks are not automatically performed on one fixed schedule for everyone.

What monitoring may be needed with HOIL-1 deficiency?

Monitoring may include heart and muscle assessment, tailored to your symptoms, genetic findings, and specialist plan. Your team may also evaluate for amylopectinosis, an abnormal buildup of sugars.

How can I reduce infection risk without giving up all social contact?

Work with your care team to create an infection-prevention plan based on your immune condition, treatments, and daily life rather than avoiding all social contact. The plan can include practical precautions and accommodations that allow safer participation in school, work, and community activities.

What support is available for the emotional strain of a rare illness?

A social worker or therapist familiar with rare chronic illness can help with fatigue, anxiety about lab results, stigma, and treatment burden. Patient advocacy groups and shared decision-making with your clinicians can also help you feel supported while planning your care.

Get notified when new evidence is published on autoinflammatory syndrome with immunodeficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (18)

1
Epstein-Barr virus-driven lymphoproliferation in inborn errors of immunity: a diagnostic and therapeutic challenge.
Barman P, Basu S, Goyal T, et al.
Expert review of clinical immunology 2024; (20(11)):1331-1346 doi:10.1080/1744666X.2024.2386427.
PMID: 39066572
2
Immunodeficiency: Overview of primary immune regulatory disorders (PIRDs).
Nelson CS, Baloh CH
Allergy and asthma proceedings 2024; (45(5)):332-339 doi:10.2500/aap.2024.45.240070.
PMID: 39294916
3
The multidisciplinary approach to diagnosing inborn errors of immunity: a comprehensive review of discipline-based manifestations.
Yazdanpanah N, Rezaei N
Expert review of clinical immunology 2024; (20(10)):1237-1259 doi:10.1080/1744666X.2024.2372335.
PMID: 38907993
4
Shared Decision-Making and Health-Related Quality of Life in the Diagnosis and Management of Patients With Inborn Errors of Immunity.
Lawrence MG, Kim VHD, Orange JS, Scherzer R
The journal of allergy and clinical immunology. In practice 2026; doi:10.1016/j.jaip.2026.07.010.
PMID: 42447994
5
The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
Romano M, Arici ZS, Piskin D, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2022; (74(7)):1102-1121 doi:10.1002/art.42139.
PMID: 35621220
6
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel.
Mekinian A, Georgin-Lavialle S, Ferrada MA, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2026; (78(3)):509-522 doi:10.1002/art.43287.
PMID: 40787890
7
Current genetic diagnostics in inborn errors of immunity.
von Hardenberg S, Klefenz I, Steinemann D, et al.
Frontiers in pediatrics 2024; (12()):1279112 doi:10.3389/fped.2024.1279112.
PMID: 38659694
8
Innovations in the care of childhood interstitial lung disease associated with connective tissue disease and immune-mediated disorders.
Samad A, Wobma H, Casey A
Pediatric pulmonology 2024; (59(9)):2321-2337 doi:10.1002/ppul.27068.
PMID: 38837875
9
LUBAC: a new player in polyglucosan body disease.
Aboujaoude A, Minassian B, Mitra S
Biochemical Society transactions 2021; (49(5)):2443-2454 doi:10.1042/BST20210838.
PMID: 34709403
10
Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1.
Obiorah IE, Patel BA, Groarke EM, et al.
Blood advances 2021; (5(16)):3203-3215 doi:10.1182/bloodadvances.2021004976.
PMID: 34427584
11
Efficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEX.
Jachiet V, Kosmider O, Beydon M, et al.
Blood 2025; (146(12)):1450-1461 doi:10.1182/blood.2024028133.
PMID: 40373272
12
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome.
Patel N, Dulau-Florea A, Calvo KR
Seminars in hematology 2021; (58(4)):204-211 doi:10.1053/j.seminhematol.2021.10.007.
PMID: 34802541
13
The multifaceted role of the E3 ubiquitin ligase HOIL-1: beyond linear ubiquitination.
Elton L, Carpentier I, Verhelst K, et al.
Immunological reviews 2015; (266(1)):208-21 doi:10.1111/imr.12307.
PMID: 26085217
14
Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood.
Welzel T, Benseler SM, Kuemmerle-Deschner JB
Frontiers in immunology 2021; (12()):516427 doi:10.3389/fimmu.2021.516427.
PMID: 33868220
15
Health-related quality of life in patients with inborn errors of immunity: A systematic review and meta-analysis.
Xiao N, Huang X, Yang D, et al.
Preventive medicine 2024; (186()):108079 doi:10.1016/j.ypmed.2024.108079.
PMID: 39053518
16
Frequency of depression and anxiety in patients with inborn errors of immunity: a cross-sectional study.
Wolff LJ, Witte T, Kahl KG, et al.
BMC psychiatry 2026; (26(1)).
PMID: 42745244
17
Work participation in inborn errors of immunity: The dual burden on patients and caregivers.
Pulvirenti F, Sgrulletti M, Radovic K, et al.
Journal of human immunity 2026; (2(6)) doi:10.70962/jhi.20260077.
PMID: 42911122
18
Inborn errors of immunity: a structured model for paediatric-to-adult transition of care.
Civino A, Diomeda F, D'Orio C, et al.
Frontiers in immunology 2026; (17()):1813944 doi:10.3389/fimmu.2026.1813944.
PMID: 42199435

This page is for informational purposes only and does not constitute medical advice about your inborn error of immunity with autoinflammation. Your immunologist and other specialists should tailor monitoring, infection prevention, treatment, and support to your subtype, symptoms, and values.